CA2826602C - Methods for treating brain injury - Google Patents
Methods for treating brain injury Download PDFInfo
- Publication number
- CA2826602C CA2826602C CA2826602A CA2826602A CA2826602C CA 2826602 C CA2826602 C CA 2826602C CA 2826602 A CA2826602 A CA 2826602A CA 2826602 A CA2826602 A CA 2826602A CA 2826602 C CA2826602 C CA 2826602C
- Authority
- CA
- Canada
- Prior art keywords
- noise
- composition
- nac
- exposure
- brain injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161439671P | 2011-02-04 | 2011-02-04 | |
| US61/439,671 | 2011-02-04 | ||
| PCT/US2012/023855 WO2012106654A1 (en) | 2011-02-04 | 2012-02-03 | Methods for treating brain injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2826602A1 CA2826602A1 (en) | 2012-08-09 |
| CA2826602C true CA2826602C (en) | 2019-06-11 |
Family
ID=46603106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2826602A Active CA2826602C (en) | 2011-02-04 | 2012-02-03 | Methods for treating brain injury |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US9289404B2 (https=) |
| EP (1) | EP2670403B1 (https=) |
| JP (2) | JP6099574B2 (https=) |
| AU (1) | AU2012211989B2 (https=) |
| CA (1) | CA2826602C (https=) |
| ES (1) | ES2893825T3 (https=) |
| IL (2) | IL227768A (https=) |
| WO (1) | WO2012106654A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9050305B2 (en) | 2012-03-29 | 2015-06-09 | Chs Pharma, Inc. | Treatment for ischemic stroke |
| WO2014172583A2 (en) * | 2013-04-18 | 2014-10-23 | Jinsheng Zhang | Compositions and methods utilizing phosphodiesterase inhibitors to treat blast-induced tinnitus and/or hearing loss |
| US20180256756A1 (en) * | 2015-09-18 | 2018-09-13 | Oklahoma Medical Research Foundation | Method of transporting an agent across blood-brain, blood-cochlear or blood-cerebrospinal fluid barrier |
| HRP20241559T1 (hr) * | 2016-05-18 | 2025-02-14 | Sound Pharmaceuticals Incorporated | Ebselen za uporabu u liječenju menierove bolesti |
| CN110248650A (zh) * | 2016-10-31 | 2019-09-17 | 霍夫耳科研究所 | 用于增强突触发生和神经突发生的方法 |
| KR20190119046A (ko) | 2017-01-19 | 2019-10-21 | 오톨로직 파마슈틱스, 인크. | N-아세틸시스테인의 제제 및 이의 용도 |
| US11617731B2 (en) | 2017-04-28 | 2023-04-04 | Axcella Health, Inc. | Amino acid compositions and their use for the treatment of traumatic brain injury |
| WO2019036442A1 (en) * | 2017-08-14 | 2019-02-21 | Axcella Health Inc. | AMINO ACIDS BRANCHED FOR THE TREATMENT OF NEURONAL INJURY |
| AU2018335160B2 (en) | 2017-09-20 | 2024-05-09 | Oklahoma Medical Research Foundation | Treatment of drug resistant gliomas |
| WO2019084543A1 (en) * | 2017-10-27 | 2019-05-02 | Beyond Barriers Therapeutics, Inc. | ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS |
| US20210137861A1 (en) * | 2018-05-03 | 2021-05-13 | Hough Ear Institute | Methods for reducing accumulated pathologic tau protein |
| WO2020018675A1 (en) * | 2018-07-18 | 2020-01-23 | The Regents Of The University Of California | Multimodal neuroimaging-based diagnostic systems and methods for detecting tinnitus |
| WO2020023755A1 (en) * | 2018-07-26 | 2020-01-30 | CHS Pharma Inc. | Treatment for ischemic stroke |
| AU2019339352B2 (en) * | 2018-09-12 | 2025-05-22 | Hough Ear Institute | Methods for treating hearing loss incident to cochlear implant surgery |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5488145A (en) | 1993-12-23 | 1996-01-30 | Oklahoma Medical Research Foundation | 2,4-disulfonyl phenyl butyl nitrone, its salts, and their use as pharmaceutical free radical traps |
| WO2000027376A2 (de) | 1998-10-26 | 2000-05-18 | Michael Schedler | Verwendung von thiolverbindungen, oxidoreduktasen und/oder hydrolasen zur behandlung des tinnitus, insbesondere des chronischen tinnitus |
| AU1574701A (en) | 1999-10-22 | 2001-04-30 | Wrair Walter Reed Army Institute Of Research | A pharmaceutical composition containing pglu-glu-pro-nh2 and method for treating diseases and injuries to the brain, spinal cord and retina using same |
| SE0001916D0 (sv) * | 2000-05-23 | 2000-05-23 | Astrazeneca Ab | Novel formulation |
| US6428474B1 (en) | 2000-05-24 | 2002-08-06 | Sol Weiss | Surgical instrument |
| US7115666B2 (en) | 2002-10-15 | 2006-10-03 | Renovis, Inc. | Nitrone compounds, pharmaceutical compositions containing the same and methods for treating inflammation and neuropathic pain |
| CA2851972C (en) | 2004-01-23 | 2015-06-23 | Cornell Research Foundation, Inc. | Methods for reducing oxidative damage |
| US20090234011A1 (en) | 2005-04-21 | 2009-09-17 | Goldstein Glenn A | N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress |
| WO2008001386A2 (en) | 2006-06-29 | 2008-01-03 | L.R.S. Ortho Ltd. | System and method for locating of distal holes of an intramedullary nail |
| AU2007277193B2 (en) * | 2006-07-25 | 2013-06-13 | Hough Ear Institute | Methods for treating acute acoustic trauma |
| US8784870B2 (en) * | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
| US9289462B2 (en) | 2008-09-17 | 2016-03-22 | Terry Gage | Method for medical treatment utilizing glutathione |
-
2012
- 2012-02-03 ES ES12742491T patent/ES2893825T3/es active Active
- 2012-02-03 CA CA2826602A patent/CA2826602C/en active Active
- 2012-02-03 JP JP2013552693A patent/JP6099574B2/ja active Active
- 2012-02-03 EP EP12742491.9A patent/EP2670403B1/en active Active
- 2012-02-03 AU AU2012211989A patent/AU2012211989B2/en active Active
- 2012-02-03 WO PCT/US2012/023855 patent/WO2012106654A1/en not_active Ceased
- 2012-02-03 US US13/983,515 patent/US9289404B2/en active Active
-
2013
- 2013-08-01 IL IL227768A patent/IL227768A/en active IP Right Grant
-
2016
- 2016-02-18 US US15/046,676 patent/US9642823B2/en active Active
- 2016-09-19 IL IL247911A patent/IL247911B/en active IP Right Grant
-
2017
- 2017-01-27 US US15/418,406 patent/US10022346B2/en active Active
- 2017-02-21 JP JP2017029662A patent/JP6286589B2/ja active Active
- 2017-06-23 US US15/632,230 patent/US10111843B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10111843B2 (en) | 2018-10-30 |
| WO2012106654A1 (en) | 2012-08-09 |
| US10022346B2 (en) | 2018-07-17 |
| US20170202797A1 (en) | 2017-07-20 |
| US20160158173A1 (en) | 2016-06-09 |
| JP2014511374A (ja) | 2014-05-15 |
| IL227768A0 (en) | 2013-09-30 |
| US9289404B2 (en) | 2016-03-22 |
| EP2670403B1 (en) | 2021-08-18 |
| ES2893825T3 (es) | 2022-02-10 |
| CA2826602A1 (en) | 2012-08-09 |
| US20140187631A1 (en) | 2014-07-03 |
| JP6099574B2 (ja) | 2017-03-22 |
| EP2670403A1 (en) | 2013-12-11 |
| US9642823B2 (en) | 2017-05-09 |
| JP2017137321A (ja) | 2017-08-10 |
| EP2670403A4 (en) | 2014-07-09 |
| JP6286589B2 (ja) | 2018-02-28 |
| IL227768A (en) | 2016-10-31 |
| IL247911B (en) | 2021-05-31 |
| IL247911A0 (en) | 2016-11-30 |
| AU2012211989B2 (en) | 2017-03-02 |
| US20170281583A1 (en) | 2017-10-05 |
| AU2012211989A1 (en) | 2013-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2826602C (en) | Methods for treating brain injury | |
| EP1562566B1 (en) | Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride | |
| CN102256596B (zh) | 用于增强对流递送到中枢神经中心的脂质体组合物 | |
| AU2013358968B2 (en) | Compositions and methods comprising polyethylene glycol and magnesium for treatment of neuronal injury | |
| Hou et al. | Novel SS-31 modified liposomes for improved protective efficacy of minocycline against drug-induced hearing loss | |
| JP7003045B2 (ja) | 神経変性の治療のための方法及び医薬組成物 | |
| Elkomy et al. | Intranasal trimethyl chitosan-coated emulsomes containing tizanidine as brain-targeted therapy in spasticity: formulation, optimization, and pharmacokinetic assessment | |
| AU2009236427A1 (en) | Biological markers and response to treatment for pain, inflammation, neuronal or vascular injury and methods of use | |
| Fan et al. | Delivering the acetylcholine neurotransmitter by nanodrugs as an effective treatment for Alzheimer's disease | |
| US20210128596A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
| US20230364192A1 (en) | Modulation of beta cell regeneration through gpr75 signaling | |
| CA3218667A1 (en) | Ph-responsive nanoparticles for treating cancer | |
| JP2002503209A (ja) | 著しく改善された抗腫瘍活性によるリポソーム抗腫瘍療法 | |
| RU2777871C1 (ru) | Способ лечения нейродегенеративных заболеваний | |
| US20230132378A9 (en) | Compositions and methods for treating hemorrhagic stroke | |
| EP1471901B1 (en) | Spermidine derivative for the treatment of chronic neurodegenerative diseases | |
| Bartnik et al. | Cell-permeant calcium buffer induced neuroprotection after cortical devascularization | |
| Deidda | Retinal neurodegeneration and an innovative nanostructured approach in an iron overload in vivo model | |
| Liu et al. | Liposome-Encapsulated Rutin Attenuates Cisplatin-Induced Ototoxicity via Suppression of P53-Associated Oxidative Injury | |
| Zhang et al. | Mesoporous catechin nanocarriers potentiate curcumin to treat osteoarthritis via synergistic antioxidant and macrophage repolarization | |
| WO2025231430A1 (en) | Compositions and methods for localized adipocyte cell death | |
| Lin et al. | Neuroprotection of Kynurenic Acid-Loaded Micelles for in Vitro and in Vivo Parkinson's Disease Models |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20170126 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD Year of fee payment: 13 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250203 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250203 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260317 |